Plazomicin

(Zemdri®)

Plazomicin

Drug updated on 12/19/2023

Dosage FormInjection (intravenous; 50 mg/mL in a single-dose vial containing plazomicin sulfate equivalent to 500 mg plazomicin free base)
Drug ClassAminoglycoside antibacterials
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI) including pyelonephritis.

Product Monograph / Prescribing Information

Document TitleYearSource
Zemdri (plazomicin) Prescribing Information.2021Cipla USA, Inc. Warren, NJ

Randomized Controlled Trials


Sex Distribution:

F:53%
M:47%
388Subjects

Year:

2019

Source:New England Journal of Medicine

Clinical Practice Guidelines